Shingles, also referred to as herpes zoster ... With the aim to positively impact the health of 2.5 billion people by the end of the decade, GSK prioritises innovation in vaccines and specialty ...

Kennedy is well known for his anti-vaccine stances and his support for alternative therapies. He’s openly criticized the FDA ...

Fewer jabs GSK shares fell owing to a “disappointing” demand for its vaccines during the third quarter of this year. The ...

Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...

Medical experts have called for more health-care resources and education targeting women, children and the elderly during the ...

Dynavax is giving up work on its combination vaccine for tetanus, diphtheria and acellular pertussis (Tdap) after mulling phase 1 data for the shot. | Dynavax is giving up on its combination vaccine ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

The collaboration agreement was signed by Dr. Ramadan Al Blooshi, Advisor to the Director General and Acting Director of the ...

The global sales of attenuated vaccines are projected to soar, with an estimated worth of USD 5,068.2 million in 2024 and anticipated to reach USD 9,693.9 million by 2034. This growth trajectory ...

GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.

GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.

FTSE 100 hits 2-month low on healthcare drag; midcap stocks grow as UK new budget less punitive. Explore market shifts and stock reactions.